{"id":"https://openalex.org/W2003145502","doi":"https://doi.org/10.1002/pds.1270","title":"Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs)","display_name":"Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs)","publication_year":2006,"publication_date":"2006-01-01","ids":{"openalex":"https://openalex.org/W2003145502","doi":"https://doi.org/10.1002/pds.1270","mag":"2003145502","pmid":"https://pubmed.ncbi.nlm.nih.gov/16783834"},"language":"en","primary_location":{"id":"doi:10.1002/pds.1270","doi":"https://doi.org/10.1002/pds.1270","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pds.1270","pdf_url":null,"source":{"id":"https://openalex.org/S140231191","display_name":"Pharmacoepidemiology and Drug Safety","issn_l":"1053-8569","issn":["1053-8569","1099-1557"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and Drug Safety","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000303989","display_name":"Karin Hedenmalm","orcid":"https://orcid.org/0000-0002-9544-9163","observed_orcids":["https://orcid.org/0000-0002-9544-9163"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I1319126558","display_name":"Medical Products Agency","ror":"https://ror.org/0356c4a29","country_code":"SE","type":"government","lineage":["https://openalex.org/I1319126558"]}],"countries":["SE"],"is_corresponding":true,"raw_author_name":"Karin Hedenmalm","raw_affiliation_strings":["Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. karin.hedenmalm@mpa.se","Clinical Trial Unit, Medical Products Agency, PO Box 26, SE\u2010751 03 Uppsala, Sweden","Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, and Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. karin.hedenmalm@mpa.se","institution_ids":["https://openalex.org/I123387679"]},{"raw_affiliation_string":"Clinical Trial Unit, Medical Products Agency, PO Box 26, SE\u2010751 03 Uppsala, Sweden","institution_ids":["https://openalex.org/I1319126558"]},{"raw_affiliation_string":"Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, and Clinical Trial Unit, Medical Products Agency, Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I1319126558"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042991274","display_name":"Anders Sundstr\u00f6m","orcid":"https://orcid.org/0000-0003-2337-3371","observed_orcids":["https://orcid.org/0000-0003-2337-3371"]},"institutions":[{"id":"https://openalex.org/I1319126558","display_name":"Medical Products Agency","ror":"https://ror.org/0356c4a29","country_code":"SE","type":"government","lineage":["https://openalex.org/I1319126558"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anders Sundstr\u00f6m","raw_affiliation_strings":["Pharmacovigilance Unit, Medical Products Agency, Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacovigilance Unit, Medical Products Agency, Uppsala, Sweden","institution_ids":["https://openalex.org/I1319126558"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031025442","display_name":"Olav Spigset","orcid":"https://orcid.org/0000-0001-7902-9014","observed_orcids":["https://orcid.org/0000-0001-7902-9014"]},"institutions":[{"id":"https://openalex.org/I204778367","display_name":"Norwegian University of Science and Technology","ror":"https://ror.org/05xg72x27","country_code":"NO","type":"education","lineage":["https://openalex.org/I204778367"]},{"id":"https://openalex.org/I4210104358","display_name":"St Olav's University Hospital","ror":"https://ror.org/01a4hbq44","country_code":"NO","type":"healthcare","lineage":["https://openalex.org/I4210104358"]}],"countries":["NO"],"is_corresponding":false,"raw_author_name":"Olav Spigset","raw_affiliation_strings":["Department of Clinical Pharmacology, St. Olav University Hospital and Norwegian University of Science and Technology, Trondheim, Norway"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, St. Olav University Hospital and Norwegian University of Science and Technology, Trondheim, Norway","institution_ids":["https://openalex.org/I204778367","https://openalex.org/I4210104358"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5000303989"],"corresponding_institution_ids":["https://openalex.org/I123387679","https://openalex.org/I1319126558"],"apc_list":{"value":4650,"currency":"USD","value_usd":4650},"apc_paid":null,"fwci":2.6083,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":{"value":0.86319613,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"15","issue":"10","first_page":"719","last_page":"725"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11167","display_name":"Hair Growth and Disorders","score":0.027699999511241913,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alopecia","display_name":"hair loss","score":0.9980000257492065},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9929999709129333},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.875},{"id":"https://openalex.org/keywords/sertraline","display_name":"sertraline","score":0.9879999756813049},{"id":"https://openalex.org/keywords/citalopram","display_name":"citalopram","score":1.0},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8169999718666077},{"id":"https://openalex.org/keywords/spontaneous-reporting","display_name":"spontaneous reporting","score":0.6809999942779541},{"id":"https://openalex.org/keywords/reporting-rates","display_name":"reporting rates","score":0.5009999871253967},{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.5809999704360962}],"concepts":[{"id":"https://openalex.org/C2777669559","wikidata":"https://www.wikidata.org/wiki/Q407617","display_name":"Sertraline","level":4,"score":0.8719921112060547},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8516979813575745},{"id":"https://openalex.org/C2777490545","wikidata":"https://www.wikidata.org/wiki/Q409672","display_name":"Citalopram","level":4,"score":0.643578290939331},{"id":"https://openalex.org/C23276603","wikidata":"https://www.wikidata.org/wiki/Q158230","display_name":"Pharmacoepidemiology","level":3,"score":0.5677245855331421},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.4903593063354492},{"id":"https://openalex.org/C2780092697","wikidata":"https://www.wikidata.org/wiki/Q7455053","display_name":"Serotonin reuptake inhibitor","level":4,"score":0.46776196360588074},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.462004154920578},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.4319232106208801},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4302806258201599},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.394669771194458},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.35728344321250916},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.3007361590862274},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2468070089817047},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.19859912991523743},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.13115420937538147},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.1098586916923523},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000505","descriptor_name":"Alopecia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D000505","descriptor_name":"Alopecia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D001499","descriptor_name":"Bayes Theorem","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013548","descriptor_name":"Sweden","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D014944","descriptor_name":"World Health Organization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015283","descriptor_name":"Citalopram","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D017891","descriptor_name":"Pharmacoepidemiology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020280","descriptor_name":"Sertraline","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/pds.1270","doi":"https://doi.org/10.1002/pds.1270","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pds.1270","pdf_url":null,"source":{"id":"https://openalex.org/S140231191","display_name":"Pharmacoepidemiology and Drug Safety","issn_l":"1053-8569","issn":["1053-8569","1099-1557"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and Drug Safety","raw_type":"journal-article"},{"id":"pmid:16783834","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16783834","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoepidemiology and drug safety","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W144460738","https://openalex.org/W205557179","https://openalex.org/W1428728879","https://openalex.org/W1973266281","https://openalex.org/W1988977860","https://openalex.org/W2015487160","https://openalex.org/W2017008233","https://openalex.org/W2051165301","https://openalex.org/W2082876349","https://openalex.org/W2084477712","https://openalex.org/W2086249059","https://openalex.org/W2140124499","https://openalex.org/W2324576701","https://openalex.org/W2409010380","https://openalex.org/W2420466742","https://openalex.org/W2609231501","https://openalex.org/W3028071611","https://openalex.org/W4206532113","https://openalex.org/W4232514332","https://openalex.org/W4237854050"],"related_works":["https://openalex.org/W4229447213","https://openalex.org/W4246711227","https://openalex.org/W4206532113","https://openalex.org/W2091122825","https://openalex.org/W2747376807","https://openalex.org/W4392163168","https://openalex.org/W7128753251","https://openalex.org/W4225274198","https://openalex.org/W1978587469","https://openalex.org/W2094772998"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"study":[2],"the":[3,38,46,57,62,73,80,104,107,126,185,223,244],"association":[4,20,194],"between":[5,99,243],"alopecia":[6,33,100,117,150,196,207,239],"and":[7,17,54,101,200,247],"selective":[8],"serotonin":[9],"reuptake":[10],"inhibitors":[11],"(SSRIs)":[12],"by":[13,18],"estimating":[14],"reporting":[15,147,180],"rates":[16,181],"making":[19],"comparisons":[21],"within":[22,106],"databases":[23],"of":[24,32,40,61,75,83,103,113,116,128,135,149,222,238],"adverse":[25],"drug":[26],"reactions":[27],"(ADRs).":[28],"METHODS:":[29],"All":[30,139],"reports":[31,115,124,142,164,172],"with":[34,156,159,195,206],"marketed":[35],"SSRIs":[36,105],"until":[37,72],"end":[39,74],"2004":[41,76],"were":[42,77,118,182,218],"identified":[43,119],"in":[44,55,70,120,151,179,197,208,212,251,254],"SWEDIS,":[45],"national":[47],"Swedish":[48,84],"database":[49,60],"for":[50,184,220],"spontaneously":[51],"reported":[52],"ADRs,":[53],"Vigibase,":[56,209],"international":[58],"ADR":[59,233],"World":[63],"Health":[64],"Organization.":[65],"Total":[66],"SSRI":[67],"sales":[68],"volumes":[69],"Sweden":[71,152],"obtained":[78],"from":[79],"National":[81],"Corporation":[82],"Pharmacies.":[85],"The":[86,146,236],"Bayes'":[87],"Confidence":[88],"Propagation":[89],"Neural":[90],"Network":[91],"(BCPNN)":[92],"method":[93],"was":[94,132,153,203],"used":[95],"to":[96,229,234,241],"estimate":[97],"associations":[98,217],"each":[102],"two":[108,123,129],"databases.":[109],"RESULTS:":[110],"A":[111],"total":[112,134],"27":[114],"SWEDIS.":[121,213],"As":[122],"concerned":[125,143],"use":[127],"SSRIs,":[130,246],"there":[131],"a":[133,191,231],"29":[136],"drug-ADR":[137],"combinations.":[138],"except":[140],"three":[141],"women":[144,252],"(88.9%).":[145],"rate":[148],"significantly":[154,204],"higher":[155,250],"sertraline":[157],"compared":[158],"citalopram;":[160],"20.1":[161],"(95%CI":[162,170],"10.7-34.4)":[163],"per":[165,173],"million":[166,174],"patient-years":[167],"versus":[168],"4.5":[169],"1.8-9.3)":[171],"patient-years.":[175],"No":[176,214],"significant":[177,193,216],"differences":[178],"noted":[183],"remaining":[186],"SSRIs.":[187,225,235],"Sertraline":[188],"also":[189],"showed":[190],"statistically":[192,215],"both":[198],"SWEDIS":[199],"Vigibase.":[201],"Citalopram":[202],"associated":[205],"but":[210],"not":[211],"found":[219],"any":[221],"other":[224],"CONCLUSIONS:":[226],"Alopecia":[227],"appears":[228],"be":[230,249],"rare":[232],"risk":[237],"seems":[240],"vary":[242],"different":[245],"might":[248],"than":[253],"men.":[255]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}